Results 231 to 240 of about 18,682 (303)

Chimeric Antigen Receptor T‐Cells in Myasthenia Gravis: Advances, Safety Challenges, and Future Directions

open access: yesMuscle &Nerve, Volume 73, Issue 6, Page 942-951, June 2026.
ABSTRACT This review examines the emerging application of chimeric antigen receptor (CAR) T‐cell therapy in myasthenia gravis (MG), with emphasis on safety, efficacy signals, and future therapeutic potential in treatment‐refractory disease. A comprehensive literature search was conducted across PubMed, medRxiv, bioRxiv, and Google Scholar for studies ...
Tobias Hegelmaier   +7 more
wiley   +1 more source

Changes in DOM Quality Determine Prokaryotic Activities and Extracellular Release in the NW Mediterranean Sea: An Experimental Approach

open access: yesEnvironmental Microbiology Reports, Volume 18, Issue 3, June 2026.
Changes in DOM composition influence prokaryotic species growth in the Mediterranean Sea, shaping their metabolic responses and organic matter processing. In our study, higher DOP consumption and alkaline phosphatase activity led to the accumulation of recalcitrant DOM, highlighting how microbial community shifts drive distinct pathways in carbon ...
Eva Ortega‐Retuerta   +9 more
wiley   +1 more source

Manufacturing and clinical applications of non‐CAR‐T immune effector cells

open access: yes
Transfusion, EarlyView.
Thane Kubik   +2 more
wiley   +1 more source

Plasma Activated Water (PAW) in Organic Cultivation: An Experimental Study on Soil Properties and Plant Responses

open access: yesEnvironmental Microbiology Reports, Volume 18, Issue 3, June 2026.
This study demonstrates that PAW enhances microbial activity and nutrient cycling in organically managed soils, highlighting its potential for organic agricultural practices. ABSTRACT Plasma‐activated water (PAW), known for containing reactive oxygen and nitrogen species (RONS), is used to improve different agronomic traits in crops.
Zakirul Islam   +4 more
wiley   +1 more source

Fenofibrate potentiates the therapeutic efficacy of EZH2 inhibitors on melanoma via TRIM21‐ and OTUD4‐mediated EZH2 ubiquitination

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 11, Page 2675-2694, June 2026.
Background and Purpose EZH2 (enhancer of zeste homologue 2) inhibitors are an emerging class of drugs that target epigenetic regulation. However, their efficacy in solid tumours has been limited, partly due to drug‐induced upregulation of fatty acid synthesis.
Rui Cheng   +10 more
wiley   +1 more source

Loss of TRPV4 is insufficient to promote repair in a spinal cord injury contusion model. [PDF]

open access: yesSci Rep
Mertens M   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy